Companies Cryptocurrencies
Ascendis Pharma A/S
Ascendis Pharma A/S
Exchange: Nasdaq Global Select
IPO Date: 28/01/2015
CEO: Mr. Jan Moeller Mikkelsen
Biotechnology Healthcare 🔗
  • ASND
  • price
  • market cap
  • changes
If you bought

shares of Ascendis Pharma A/S (ASND) on
You would have made
Old Price $12 Current Price $12

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The firm is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. The company is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.

Address: Tuborg Boulevard 5 Hellerup 2900

Stay updated.